<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058900</url>
  </required_header>
  <id_info>
    <org_study_id>OUH-DC-FLORA-01</org_study_id>
    <nct_id>NCT03058900</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis</brief_title>
  <acronym>FLORA</acronym>
  <official_title>Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Peripheral Psoriatic Arthritis: A 6-month, Double-Blinded, Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Rheumatism Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense Patient Explorative data Network (OPEN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Psoriasis Association, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An abnormal intestinal microbiota may be the mediator of the common inflammatory pathways
      seen in psoriatic arthritis. This study will explore clinical aspects associated with
      modifying the intestinal microbiota by infusing fecal donor microbiota into the small
      intestine of psoriatic arthritis patients with a minimum of three swollen joints despite at
      least three months of methotrexate treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent years have seen growing recognition of the complexity of the role of the microbiota in
      shaping the immune system and its potential effects for health and disease. In particular,
      the gut bacteria composition has been associated with the pathogenesis of autoimmune and
      inflammatory diseases. Intriguingly, presence of intestinal inflammation in psoriatic
      arthritis (PsA) patients has been documented in several studies. Also, in genetically
      predisposed patients reactive arthritis, which share some of the clinical manifestations of
      PsA, can be triggered by certain types of bacterial gut infections. Furthermore, a recent
      study has reported that several intestinal bacteria including Akkermansia and Ruminoccocus,
      which are known to play an important role in maintaining gut homeostasis, were practically
      absent in PsA patients. Mechanisms through which the microbiota may be involved in the
      pathogenesis of PsA include an abnormal activation of the gut-associated lymphoid tissue
      (GALT) and/or an altered mucosal permeability thus compromising the capacity of the intestine
      to provide adequate containment of luminal microorganisms and molecules.

      By conducting a double-blinded, randomized, placebo-controlled trial of a non-related donor
      fecal microbiota transplantation (FMT) infused into the small intestine, this study will
      reveal whether FMT is more effective than an identically appearing placebo (saline) in
      reducing disease activity in psoriatic arthritis patients presenting with a minimum of three
      swollen joints despite at least three months of s.c. methotrexate treatment (maximal
      tolerable dosis ≥ 15 mg/week). All patients will throughout the study continue their
      individual treatment with weekly s.c. methotrexate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Double-Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>6 months (+/- 14 days)</time_frame>
    <description>Proportion of patients in each group who experience treatment failure according to shared decision making between patient and rheumatologist defined as at least one of the following:
Need for more than 1 intra-articular glucocorticoid injection due to disease activity.
Need for change to other conventional DMARDs (at the moment oral leflunomide, sulfasalazin or ciclosporin) according to the updated Danish guideline treatment due to disease activity.
Need for biologic treatment according to the updated Danish guideline treatment due to severe disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Short Health Assessment Questionnaire (2-page HAQ)</measure>
    <time_frame>Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Change from baseline in the Short Health Assessment Questionnaire (2-page HAQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Dermatology Life Quality Index (DLQI) Questionnaire</measure>
    <time_frame>Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Change from baseline in the Dermatology Life Quality Index (DLQI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Gastrointestinal Side Effects</measure>
    <time_frame>Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Change from baseline in gastrointestinal symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Other Side Effects</measure>
    <time_frame>Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Change from baseline in other (non-gastrointestinal) symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The American College of Rheumatology (ACR) Response Criteria</measure>
    <time_frame>Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Proportion of patients in each group achieving
ACR20 response criteria
ACR50 response criteria
ACR70 response criteria
A patient will be considered as improved according to the ACR20/50/70 response criteria if she/he has at least 20/50/70% improvement in the two following measures: Tender joint count (68) and swollen joint count (66), and at least 3 of the following 5 measures: Patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ) score, acute phase reactant (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Psoriatic Arthritis Response Criteria (PsARC)</measure>
    <time_frame>Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Proportion of patients in each group achieving PsARC response criteria. A patient will be considered as improved according to the PsARC response criteria if she/he has an improvement in either joint swelling or tenderness, and in any of 4 other measures: Patient global assessment of articular disease; physician global assessment of articular disease; joint pain or tenderness; joint swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index</measure>
    <time_frame>Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Change from baseline in SPARCC Enthesitis Index in the subset of patients who have enthesitis at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Change from baseline in the Psoriasis Area Severity Index (PASI) in the subset of patients who have psoriasis at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dactylitis</measure>
    <time_frame>Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)</time_frame>
    <description>Change from baseline in the number of digits affected with dactylitis in the subset of patients who have dactylitis at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>6 months (+/- 14 days)</time_frame>
    <description>Number of adverse events in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>6 months (+/- 14 days)</time_frame>
    <description>Number of patients with at least one adverse event in each group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation (FMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal microbiota transplantation (FMT)</intervention_name>
    <description>One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.</description>
    <arm_group_label>Fecal microbiota transplantation (FMT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Drug: Placebo (saline)</intervention_name>
    <description>One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.</description>
    <arm_group_label>Placebo (saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (MTX)</intervention_name>
    <description>Weekly s.c. methotrexate in maximum tolerable dosis</description>
    <arm_group_label>Fecal microbiota transplantation (FMT)</arm_group_label>
    <arm_group_label>Placebo (saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of psoriatic arthritis according to the Classification Criteria for
             Psoriatic Arthritis (CASPAR criteria).

          -  Presence of active peripheral psoriatic arthritis defined as ≥ 3 swollen joints.

          -  S.c methotrexate (≥ 15mg/week (maximal tolerable dosage)) for a minimum of 3 months
             prior to study inclusion.

        Exclusion Criteria:

          -  Other rheumatic diseases than PsA.

          -  Clinical suspicion of current axial disease activity.

          -  History of severe MTX toxicity or allergic reactions.

          -  Current biological treatment and biological treatment within the last 6 months.

          -  Inflammatory bowel disease, celiac disease, food allergy, or other intestinal
             diseases.

          -  Current cancer or severe chronic infections.

          -  Pregnant or breastfeeding women.

          -  Systemic and/or local intra-articular or peritendinous steroid injections within 3
             months of inclusion.

          -  NSAIDs within 14 days or non-MTX DMARD treatment within three months of inclusion.

          -  Antibiotics within 3 months of inclusion.

          -  Not wishing to participate or unsuited for project evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torkell J. Ellingsen, Prof. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torkell J. Ellingsen, Prof. PhD</last_name>
    <phone>+45 22397306</phone>
    <email>torkell.ellingsen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maja S. Kragsnaes, PhD student</last_name>
    <phone>+45 22982528</phone>
    <email>maja.kragsnaes@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Rheumatology at Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torkell J. Ellingsen, Prof PhD</last_name>
      <email>torkell.ellingsen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Maja S. Kragsnaes, PhD student</last_name>
      <email>maja.kragsnaes@dadlnet.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Maja S. Kragsnaes, PhD student</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Torkell J. Ellingsen, Prof PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diagnostic Centre at Silkeborg Regional Hospital</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maja S. Kragsnaes, PhD student</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Coates LC, Conaghan PG, Emery P, Green MJ, Ibrahim G, MacIver H, Helliwell PS. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2012 Oct;64(10):3150-5. doi: 10.1002/art.34536.</citation>
    <PMID>22576997</PMID>
  </reference>
  <reference>
    <citation>Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73.</citation>
    <PMID>16871531</PMID>
  </reference>
  <reference>
    <citation>Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O'Keeffe AG, Maddison PJ, Scott DL. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012 Aug;51(8):1368-77. doi: 10.1093/rheumatology/kes001. Epub 2012 Feb 17.</citation>
    <PMID>22344575</PMID>
  </reference>
  <reference>
    <citation>Statnikov A, Alekseyenko AV, Li Z, Henaff M, Perez-Perez GI, Blaser MJ, Aliferis CF. Microbiomic signatures of psoriasis: feasibility and methodology comparison. Sci Rep. 2013;3:2620. doi: 10.1038/srep02620.</citation>
    <PMID>24018484</PMID>
  </reference>
  <reference>
    <citation>Eppinga H, Konstantinov SR, Peppelenbosch MP, Thio HB. The microbiome and psoriatic arthritis. Curr Rheumatol Rep. 2014 Mar;16(3):407. doi: 10.1007/s11926-013-0407-2. Review.</citation>
    <PMID>24474190</PMID>
  </reference>
  <reference>
    <citation>Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol. 2008 Sep;1(5):364-71. doi: 10.1038/mi.2008.24. Epub 2008 Jul 9. Review.</citation>
    <PMID>19079200</PMID>
  </reference>
  <reference>
    <citation>Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C, Littman DR. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013 Nov 5;2:e01202. doi: 10.7554/eLife.01202.</citation>
    <PMID>24192039</PMID>
  </reference>
  <reference>
    <citation>Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol. 2014 Jan;26(1):101-7. doi: 10.1097/BOR.0000000000000008. Review.</citation>
    <PMID>24247114</PMID>
  </reference>
  <reference>
    <citation>Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, Marmon S, Neimann A, Brusca S, Patel T, Manasson J, Pamer EG, Littman DR, Abramson SB. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015 Jan;67(1):128-39. doi: 10.1002/art.38892.</citation>
    <PMID>25319745</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y, Lan Z, Chen B, Li Y, Zhong H, Xie H, Jie Z, Chen W, Tang S, Xu X, Wang X, Cai X, Liu S, Xia Y, Li J, Qiao X, Al-Aama JY, Chen H, Wang L, Wu QJ, Zhang F, Zheng W, Li Y, Zhang M, Luo G, Xue W, Xiao L, Li J, Chen W, Xu X, Yin Y, Yang H, Wang J, Kristiansen K, Liu L, Li T, Huang Q, Li Y, Wang J. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015 Aug;21(8):895-905. doi: 10.1038/nm.3914. Epub 2015 Jul 27.</citation>
    <PMID>26214836</PMID>
  </reference>
  <reference>
    <citation>Yeoh N, Burton JP, Suppiah P, Reid G, Stebbings S. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep. 2013 Mar;15(3):314. doi: 10.1007/s11926-012-0314-y. Review.</citation>
    <PMID>23378145</PMID>
  </reference>
  <reference>
    <citation>Scarpa R, Manguso F, D'Arienzo A, D'Armiento FP, Astarita C, Mazzacca G, Ayala F. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000 May;27(5):1241-6.</citation>
    <PMID>10813294</PMID>
  </reference>
  <reference>
    <citation>Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep. 2011 Oct;13(5):409-15. doi: 10.1007/s11926-011-0198-2.</citation>
    <PMID>21744132</PMID>
  </reference>
  <reference>
    <citation>Lindqvist U, Kristjánsson G, Pihl-Lundin I, Hagforsen E, Michaëlsson G. Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris. J Rheumatol. 2006 May;33(5):924-7. Epub 2006 Mar 15.</citation>
    <PMID>16541478</PMID>
  </reference>
  <reference>
    <citation>Morgan XC, Huttenhower C. Meta'omic analytic techniques for studying the intestinal microbiome. Gastroenterology. 2014 May;146(6):1437-1448.e1. doi: 10.1053/j.gastro.2014.01.049. Epub 2014 Jan 28. Review.</citation>
    <PMID>24486053</PMID>
  </reference>
  <reference>
    <citation>Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d'Elia H. Calprotectin in ankylosing spondylitis--frequently elevated in feces, but normal in serum. Scand J Gastroenterol. 2012 Apr;47(4):435-44. doi: 10.3109/00365521.2011.648953. Epub 2012 Jan 10.</citation>
    <PMID>22229862</PMID>
  </reference>
  <reference>
    <citation>van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.</citation>
    <PMID>23323867</PMID>
  </reference>
  <reference>
    <citation>Smith MB, Kelly C, Alm EJ. Policy: How to regulate faecal transplants. Nature. 2014 Feb 20;506(7488):290-1.</citation>
    <PMID>24558658</PMID>
  </reference>
  <reference>
    <citation>Toupin-April K, Barton J, Fraenkel L, Li L, Grandpierre V, Guillemin F, Rader T, Stacey D, Légaré F, Jull J, Petkovic J, Scholte-Voshaar M, Welch V, Lyddiatt A, Hofstetter C, De Wit M, March L, Meade T, Christensen R, Gaujoux-Viala C, Suarez-Almazor ME, Boonen A, Pohl C, Martin R, Tugwell PS. Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. J Rheumatol. 2015 Dec;42(12):2442-7. doi: 10.3899/jrheum.141205. Epub 2015 Apr 15. Review.</citation>
    <PMID>25877502</PMID>
  </reference>
  <reference>
    <citation>Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S14-8.</citation>
    <PMID>16273780</PMID>
  </reference>
  <reference>
    <citation>Faria JR, Aarão AR, Jimenez LM, Silva OH, Avelleira JC. Inter-rater concordance study of the PASI (Psoriasis Area and Severity Index). An Bras Dermatol. 2010 Sep-Oct;85(5):625-9.</citation>
    <PMID>21152786</PMID>
  </reference>
  <reference>
    <citation>Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, Sampalis J, Conner-Spady B. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009 Jun;68(6):948-53. doi: 10.1136/ard.2007.084244. Epub 2008 Jun 4.</citation>
    <PMID>18524792</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Torkell Ellingsen</investigator_full_name>
    <investigator_title>Clinical professor/Head of research and chief consultant MD PhD</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>FMT</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Intestinal microbiome</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

